Johns Hopkins Medicine’s team published clinical validation supporting what is described as the first FDA-cleared rapid urine test to aid diagnosis of invasive aspergillosis. The clearance is aimed at speeding identification in settings where early detection can determine whether patients receive prompt targeted antifungal therapy. Rapid diagnostics in invasive fungal disease are often limited by sensitivity early in disease and by the need for specialized workflows. A urine-based approach is positioned as a lower-friction pathway compared with some existing testing modalities, potentially expanding access. The immediate clinical impact will depend on how the test integrates into real-world diagnostic algorithms, including confirmatory testing and clinician decision-making thresholds.